AGA FDA Town Hall
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
5390
AGA FDA Town Hall
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
Moderators
University of Tennessee Health Science Center
Middleburg Consultants
Related Products
AGA The Mucosal Immune Response and Nonimmune Cells in IBD
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
AGA Small Intestinal Microbiome: An Underappreciated Driver of Gastrointestinal Disease and Novel Therapeutic Target
Microbiome science in the gut has focused on the study of colonic, and more frequently, fecal communities. While the upper gastrointestinal tract has significantly lower bacterial density than the colon, it still harbors a dynamic microbial community…
AGA Microbiome Therapeutics on the Horizon
This session highlights thecurrent FDA approved microbiome therapeutics and their applications and the exciting avenues being pursued for the next generation of microbiome therapeutics using gene editing and synthetic microbial communities…
AGA Role of the Microbiome in IBD
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…